Rene Russo's most recent trade in Xilio Therapeutics Inc was a trade of 1,500,258 Stock Option (right to buy) done . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 1,500,258 | 1,500,258 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 44,250 | 325,422 | - | - | Common Stock | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 44,250 | 88,500 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 2,075,000 | 2,075,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 700,000 | 700,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 700,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 473,334 | 473,334 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 473,334 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 350,000 | 350,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 350,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 239,703 | 239,703 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 239,703 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 150,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 135,134 | 135,134 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 135,134 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 100,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 50,041 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 50,041 | 50,041 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Purchase of securities on an exchange or from another person at price $ 0.68 per share. | 16 Jun 2025 | 36,289 | 281,172 | - | 0.7 | 24,680 | Common Stock |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 190,000 | 190,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 638,000 | 638,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 44,250 | 244,883 | - | - | Common Stock | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 44,250 | 132,750 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 474,000 | 474,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 177,000 | 177,000 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2023 | 700,000 | 700,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 350,000 | 350,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO AND PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Rene Russo | Director, CEO and President, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 50,041 | 50,041 | - | - | Stock Option (right to buy) | |
| Invivyd Inc | Rene Russo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2021 | 35,593 | 35,593 | - | - | Stock Option (Right to Buy) | |
| X4 Pharma Inc | Rene Russo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) |